Meta-analysis of 8 randomised and observational studies (1044 patients) in head and neck SCC: no significant difference between cisplatin- and carboplatin-based regimens in OS, PFS, LRRFS, DMFS or grade ≥3 toxicity; 5-year LRRFS modestly favoured cisplatin (2 studies).
Meta-analysisn = 1,044
Rahim et al. Efficacy and Safety of Cisplatin Versus Carboplatin for Patients With Squamous Cell Carcinoma of Head and Neck: A Systematic Review and Meta-Analysis